Li AG, et al. (2007) An acetylation switch in p53 mediates holo-TFIID recruitment. Mol Cell 28, 408-21 17996705

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

K370-ac - p53 (human) ▲

Modsite: RAHsSHLkskkGQst SwissProt Entrez-Gene Orthologous residues p53 (human): K370‑ac, p53 iso2 (human): ‑, p53 iso4 (human): K331‑ac, p53 (mouse): K367‑ac, p53 iso2 (mouse): ‑, p53 (rat): K368‑ac, p53 (rabbit): K368‑ac, p53 (green monkey): K370‑ac Characterization Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary), Saos-2 (bone cell), U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes trichostatin_A increase

K372-ac - p53 (human) ▲

Modsite: HsSHLkskkGQstsR SwissProt Entrez-Gene Orthologous residues p53 (human): K372‑ac, p53 iso2 (human): ‑, p53 iso4 (human): K333‑ac, p53 (mouse): K369‑ac, p53 iso2 (mouse): ‑, p53 (rat): K370‑ac, p53 (rabbit): K370‑ac, p53 (green monkey): K372‑ac Characterization Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary), Saos-2 (bone cell), U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes trichostatin_A increase

K373-ac - p53 (human) ▲

Modsite: sSHLkskkGQstsRH SwissProt Entrez-Gene Orthologous residues p53 (human): K373‑ac, p53 iso2 (human): ‑, p53 iso4 (human): K334‑ac, p53 (mouse): K370‑ac, p53 iso2 (mouse): ‑, p53 (rat): K371‑ac, p53 (rabbit): K371‑ac, p53 (green monkey): K373‑ac Characterization Methods used to characterize site in vivo:  immunoprecipitation, modification-specific antibody, mutation of modification site, western blotting Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary), Saos-2 (bone cell), U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes trichostatin_A increase UV increase Downstream Regulation Effect of modification (function):  molecular association, regulation Effect of modification (process):  transcription, induced Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays Induces electrophoretic visualization TAF1 (human) Bromodomain Induces in vitro, pull-down assay Comments:  enhances p53-TAF1 complex binding to the p21 promoter

K381-ac - p53 (human) ▲

Modsite: GQstsRHkkLMFktE SwissProt Entrez-Gene Orthologous residues p53 (human): K381‑ac, p53 iso2 (human): ‑, p53 iso4 (human): K342‑ac, p53 (mouse): K378‑ac, p53 iso2 (mouse): ‑, p53 (rat): K379‑ac, p53 (rabbit): K379‑ac, p53 (green monkey): K381‑ac Characterization Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary), Saos-2 (bone cell), U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes trichostatin_A increase

K382-ac - p53 (human) ▲

Modsite: QstsRHkkLMFktEG SwissProt Entrez-Gene Orthologous residues p53 (human): K382‑ac, p53 iso2 (human): ‑, p53 iso4 (human): K343‑ac, p53 (mouse): K379‑ac, p53 iso2 (mouse): ‑, p53 (rat): K380‑ac, p53 (rabbit): K380‑ac, p53 (green monkey): K382‑ac Characterization Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary), Saos-2 (bone cell), U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes trichostatin_A increase UV increase Downstream Regulation Effect of modification (function):  molecular association, regulation Effect of modification (process):  transcription, induced Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays TAF1 (human) Bromodomain Induces in vitro, pull-down assay Induces electrophoretic visualization Comments:  enhances p53-TAF1 complex binding to the p21 promoter

K386-ac - p53 (human) ▲
Modsite: RHkkLMFktEGPDsD SwissProt Entrez-Gene Orthologous residues p53 (human): K386‑ac, p53 iso2 (human): ‑, p53 iso4 (human): K347‑ac, p53 (mouse): K383‑ac, p53 iso2 (mouse): ‑, p53 (rat): K384‑ac, p53 (rabbit): K384‑ac, p53 (green monkey): K386‑ac